Ensign Peak Advisors’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADPT
Ensign Peak Advisors's ADPT Position: Q3 2026 in Review
Ensign Peak Advisors increased its Adaptive Biotechnologies (ADPT) stake by 6% in Q3 2026, buying an estimated $177K and bringing the position to 127,989 shares worth $3.7M. The position accounts for 0.01% of the portfolio, ranked #640.
Ensign Peak Advisors first reported a position in ADPT in Q4 2019 and has held it in 17 quarters since. The position peaked at $5.62M in Q4 2020. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.
- Ensign Peak Advisors held 127,989 shares of Adaptive Biotechnologies worth $3.7M as of Q3 2026.
- Ensign Peak Advisors bought 7,219 Adaptive Biotechnologies shares in Q3 2026, an estimated $177K.
- Adaptive Biotechnologies made up 0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #640 holding.
- Ensign Peak Advisors first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 17 quarters since.
- Ensign Peak Advisors's Adaptive Biotechnologies position peaked at $5.62M in Q4 2020.
- 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.